What is the recommended starting dose of premixed insulin 70/30 (human insulin) at 0.3–0.4 units/kg/day, can the dose be divided two‑thirds in the morning and one‑third in the evening, and which 70/30 brand (Humulin 70/30 [insulin human] or Novolin 70/30 [insulin human]) is considered the best option in the Philippines?

Starting Dose and Dosing Schedule for 70/30 Insulin

The proposed starting dose of 0.3-0.4 units/kg/day for premixed 70/30 insulin is higher than current guideline recommendations, and yes, the 2/3 AM and 1/3 PM split is the standard evidence-based approach. However, you should start more conservatively to minimize hypoglycemia risk.

Recommended Starting Dose

According to the 2025 ADA Standards of Care, basal insulin should be initiated at 10 units per day OR 0.1-0.2 units/kg per day 1. While this guideline specifically addresses basal insulin initiation, the same conservative approach applies when starting premixed insulin regimens to avoid hypoglycemia.

Your proposed 0.3-0.4 units/kg/day is approximately double the recommended starting range and carries significant hypoglycemia risk, particularly since 70/30 contains 30% short-acting insulin that will peak postprandially. A 70 kg patient would receive 21-28 units daily at your proposed dose versus the safer 7-14 units using guideline recommendations.

Safer Initiation Strategy:

• Start at 0.1-0.2 units/kg/day total daily dose
• Divide as 2/3 before breakfast and 1/3 before dinner 11
• Titrate upward by 2 units every 3 days based on glucose monitoring 1
• For hypoglycemia without clear cause, reduce dose by 10-20% 1

Dosing Schedule: 2/3 AM and 1/3 PM

Yes, the 2/3 morning and 1/3 evening split is explicitly recommended in current guidelines 111. This distribution aligns with:

• Typical meal patterns (larger breakfast/lunch coverage with AM dose)
• Physiologic insulin requirements throughout the day
• The pharmacokinetic profile of 70/30 insulin

The FDA label for Novolin 70/30 confirms it is "typically dosed twice daily (with each dose intended to cover 2 meals or a meal and a snack)" 22, supporting this approach. Administer approximately 30 minutes before meals 2.

Best 70/30 Brand in the Philippines

Both Humulin 70/30 (Eli Lilly) and Novolin 70/30 (Novo Nordisk) are bioequivalent human insulin formulations with no clinically meaningful differences in efficacy or safety. Research comparing these formulations at 0.3 U/kg showed no differences in maximum/minimum glucose concentrations, time to peak, or areas under the curve 3.

Selection Factors:

• Cost and availability: Choose whichever is more affordable and consistently available in your local market
• Device preference: Consider whether vials or prefilled pens (FlexPen for Novolin) better suit the patient's needs 2
• Storage considerations: Both require identical storage conditions; in the Philippines' tropical climate, unopened vials can be stored at up to 25°C for up to 6 months without clinically relevant potency loss 4

Critical Safety Considerations

Hypoglycemia Risk

Starting at higher doses (0.3-0.4 units/kg/day) dramatically increases hypoglycemia risk, which can be life-threatening, cause seizures, unconsciousness, or death 2. The 30% short-acting component peaks 2-4 hours post-injection, creating dual risk periods after each dose.

Monitoring Requirements

• Increase blood glucose monitoring frequency during initiation 12
• Check fasting glucose to guide titration
• Monitor pre-dinner glucose to assess morning dose adequacy
• Assess for signs of overbasalization (elevated bedtime-to-morning differential, hypoglycemia, high glucose variability) 1

Administration Pitfalls

• Must resuspend before each injection: Roll vial 10 times or move pen up/down 20 times until uniformly white and cloudy 2
• Inject 30 minutes before meals 2—this is critical for the short-acting component to match carbohydrate absorption
• Rotate injection sites within the same region to prevent lipodystrophy 2
• Never share pens or needles between patients 2

When Higher Starting Doses May Be Appropriate

Consider insulin as first injectable at higher doses only when 1:

• A1C >10% (>86 mmol/mol)
• Blood glucose ≥300 mg/dL (≥16.7 mmol/L)
• Symptomatic hyperglycemia present
• Type 1 diabetes is a diagnostic possibility

Even in these scenarios, start conservatively and titrate rapidly rather than beginning at 0.3-0.4 units/kg/day.

Limitations of 70/30 Insulin

The fixed 70/30 ratio does not allow separate adjustment of basal versus prandial components 2. If glucose control remains inadequate, consider transitioning to a basal-bolus regimen or adding GLP-1 receptor agonists for better individualization 1.